Collegium Pharmaceutical's Presentation at National Conference
STOUGHTON, Mass. — Collegium Pharmaceutical, Inc. (Nasdaq: COLL) proudly announces its participation in the upcoming National Association of Pediatric Nurse Practitioners (NAPNAP) National Conference on Pediatric Health Care. At this important event, the company will showcase two informative poster presentations focused on the real-world data related to its neuropsychiatry product, Jornay PM, which is aimed at treating attention deficit hyperactivity disorder (ADHD).
Key Highlights of the Presentations
The presentations will take place during the NAPNAP 46th National Conference in Chicago, offering attendees valuable insights into the effectiveness of Jornay PM, a central nervous system stimulant. The data presented will reflect the real-world patients' experiences, reinforcing Collegium's commitment to enhancing treatment options for those living with ADHD.
Details of the Poster Sessions
The highlighted posters will be available for viewing on specific days at the Riverside Center Exhibit Hall in the East Tower. Attendees can find them during the following exhibit hall hours:
- Monday: 12:00 PM - 1:30 PM and 6:00 PM - 7:30 PM CT
- Tuesday: 8:00 AM - 10:00 AM and 12:15 PM - 2:15 PM CT
The presentations will cover:
- Poster #9: Real-World Persistence and Adherence with Delayed-Release/Extended-Release Methylphenidate; authors include Vamshi Ruthwik Anupindi, Swapna Munnangi, and others.
- Poster #10: Real-World Utilization of Delayed-Release/Extended-Release Methylphenidate, with similar author contributions.
Understanding ADHD and Its Challenges
ADHD is one of the most prevalent psychiatric conditions in children, often diagnosed at an early age and sometimes persisting into adulthood. Characterized by symptoms such as difficulties in maintaining attention and impulsiveness, ADHD can create challenges for children, particularly during daily routines like getting ready for school.
About JORNAY PM
JORNAY PM is an extended-release formulation of methylphenidate, specifically designed for children aged six years and older who are experiencing ADHD symptoms. Its unique delivery system allows for flexible and effective management of ADHD throughout the day. However, it is important to understand that JORNAY PM is classified as a controlled substance due to its potential for abuse, necessitating responsible usage under the supervision of a healthcare provider.
Commitment to Patient Safety
At Collegium Pharmaceutical, safeguarding the health and well-being of patients is paramount. It is vital to be aware of the serious implications linked to JORNAY PM, including risks associated with misuse and the potential for developing dependency. The company emphasizes the significance of discussions between healthcare providers and patients regarding history with substance use and the risks associated with treatment.
Safety Information and Side Effects
Patients prescribed JORNAY PM should be informed about possible side effects, which may include decreased appetite, sleep disturbances, and mood fluctuations. Parents and guardians are encouraged to closely monitor their children during treatment, keeping healthcare providers informed about any adverse reactions.
About Collegium Pharmaceutical, Inc.
Collegium is dedicated to building a well-rounded biopharmaceutical company that prioritizes the treatment of serious medical conditions. With a strong portfolio of responsible pain management options and the recent addition of Jornay PM for ADHD, Collegium is on a path of growth and innovation. Headquartered in Stoughton, Massachusetts, the company is committed to enhancing the lives of those it serves.
Frequently Asked Questions
What is the significance of the NAPNAP conference?
The NAPNAP conference is a vital platform for showcasing the latest in pediatric healthcare advancements, including updates on ADHD treatments.
What does JORNAY PM treat?
JORNAY PM is an extended-release medication specifically used for treating attention deficit hyperactivity disorder (ADHD) in children aged six and older.
Who can attend the poster presentations?
The presentations will be available to all attendees of the NAPNAP National Conference, providing key insights into ADHD treatment research.
What are the potential side effects of JORNAY PM?
Common side effects can include decreased appetite, insomnia, and mood swings, while more serious risks require careful monitoring by healthcare providers.
How does Collegium Pharmaceutical ensure safety?
Collegium emphasizes patient safety through educational initiatives and by ensuring healthcare providers are informed about potential risks associated with ADHD treatments.
